Shionogi & Co., Ltd. TSE:4507

Positive Topline Results from Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome Followed by SOC in Patients with Invasive Aspergillosis

Published June 18, 2026 at 4:00 a.m. UTC

Source: TDnet

Shionogi & Co., Ltd. (4507) Press Release

View Attachment